Skip to content
BioalmanacPeptide reference
Account
Menu

Comparison

Mazdutide vs tirzepatide

Two dual agonists that picked different second receptors. Tirzepatide added GIP; mazdutide added glucagon, which does something GIP does not.

Both build on GLP-1 and both add a second receptor, and the choice of second receptor is the whole comparison.

Tirzepatide's GIP component is thought to improve how fat tissue handles nutrients and may reduce the nausea that comes with GLP-1 agonism. Mazdutide's glucagon component raises energy expenditure directly — the same hormone that raises blood glucose, used here for what it does to metabolic rate.

That makes their side-effect and monitoring profiles different in kind rather than degree. A glucagon receptor agonist has effects on glucose and on the liver that a GIP agonist does not.

Mazdutide vs tirzepatide compared row by row
AttributeMazdutideTirzepatide
Receptor targetsGLP-1 and glucagonGLP-1 and GIP
Evidence levelApproved for another indicationApproved
RouteSubcutaneousSubcutaneous
Dosing frequencyOnce weeklyOnce weekly
Half-lifeAbout a weekAbout 5 days
Second receptor's jobRaises energy expenditureNutrient handling in fat tissue
Where approvedChinaUnited States and elsewhere

Things worth knowing

  • Adding glucagon agonism to a weight-loss drug reads as a contradiction, since glucagon raises blood glucose. The bet is that the increase in energy expenditure outweighs it and that GLP-1 agonism covers the glucose effect. That is a bet with a different risk profile from tirzepatide's.
  • Approval in one country is not approval everywhere, and mazdutide's is Chinese. The regulatory positions here differ, which is a real difference between the two and not a technicality.
  • Both escalate over weeks rather than starting at a maintenance dose, and both share the gastrointestinal effects of the class.

Full profile

Mazdutide

A GLP-1 and glucagon dual agonist approved in China in 2026. Not approved in the United States, and the US pathway is undecided.

Full profile

Tirzepatide

A once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.

Related

Another comparisonTirzepatide vs survodutideTwo dual agonists that picked different second receptors, GIP in one case and glucagon in the other, and that sit at very different stages of evidence.Another comparisonSemaglutide vs tirzepatideBoth are once-weekly incretin agonists approved for weight management. The difference is how many receptors each one acts on, and what that does to the dosing scale.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.